Vor to Participate in the JMP Securities Hematology and Oncology Summit
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, the company's President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 12:40 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Vor Biopharma (Nasdaq: VOR) announced that Dr. Robert Ang, the company's President and CEO, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 12:40 PM ET. Investors can access a live webcast of the chat on the company’s website, with an archived replay available afterward. Vor Biopharma focuses on transforming care for blood cancer patients by engineering hematopoietic stem cells for targeted therapies following transplantation.
Details
News Market Reaction – VOR
The recorded move for VOR in the trading session of this news was -4.00%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will be participating in a fireside chat at the JMP Securities Hematology and Oncology Summit.
JMP Securities Hematology and Oncology Summit
Date: Monday, December 6, 2021
Time: 12:40 PM ET
A live webcast of the fireside chat will be available via the Investors section of the Company's website at www.vorbio.com. An archived replay of the webcast will also be available following the conference.
About Vor Biopharma
Vor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies post-transplant. For more information, visit: www.vorbio.com.
Contacts:
Investors:
Chris Brinzey
ICR Westwicke
+1 339-970-2843
chris.brinzey@westwicke.com
Media:
Sarah Spencer
Vice President, Corporate Communications, Vor
+1 857-242-6076
sspencer@vorbio.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.